Phosphorylation of the BH3 (Bcl-2 homology domain 3)-only protein BAD (Bcl-2/Bcl-X L -antagonist, causing cell death) can either directly disrupt its association with the pro-survival proteins Bcl-X L and/or Bcl-2, or cause association of BAD with 14-3-3 proteins. In the present study, we further characterize phosphorylation of BAD at Ser 170 , a unique site with unclear function. We provide further evidence that mutation of Ser 170 to a phospho-mimetic aspartic acid residue (S170D) can have a profound inhibitory effect on the pro-apoptosis function of BAD. Furthermore, mutated BAD with an alanine substitution inhibited cell proliferation, slowing progression specifically through Sphase. We identify the kinase responsible for phosphorylation at this site as CaMKII-γ (γ isoform of Ca 2 + /calmodulin-dependent kinase II), but not the other three isoforms of CaMKII, revealing an extraordinary specificity among these closely related kinases. Furthermore, cytokine treatment increased BAD-Ser 170 -directed CaMKII-γ activity and phosphorylation of CaMKII-γ at an activating site, and CaMKII activity directed to the BAD-Ser 170 site was elevated during S-phase. Treating cells with a selective inhibitor of CaMKII caused apoptosis in cells expressing BAD, but not in cells expressing the BAD-S170D mutant. The present study provides support for BAD-Ser 170 phosphorylation playing a key role not only in regulating BAD's pro-apoptotic activity, but also in cell proliferation.
INTRODUCTION
Mammalian cells have an intricate network of signalling molecules to sense and interpret internal and external signals; the balance of these events direct cell proliferation, quiescence or apoptosis. Haemopoietic cells serve as excellent model systems to study apoptosis since their survival is dependent on specific cytokines that maintain cell proliferation and viability [1] [2] [3] [4] . Death of cytokine-deprived haemopoietic cells proceeds via the mitochondrial pathway, involving regulation of various Bcl-2 family proteins [5] [6] [7] . The Bcl-2 family of signalling proteins act as effectors of death or survival signals, via interactions mediated by BH (Bcl-2 homology) domains. The members containing only one BH3 domain can regulate the activity of the other proteins via specific interactions. One highly regulated BH3-only protein is BAD (Bcl-2/Bcl-X L -antagonist, causing cell death), whose proapoptotic function is inhibited by phosphorylation at multiple sites [7, 8] . Through its multiple phosphorylation sites (Ser 112 , Ser 128 , Ser 136 , Ser 155 and Ser 170 in the murine protein, with all sites being conserved in human BAD) it is able to converge signals from numerous pathways and sensitize cells to apoptotic signals when upstream kinase pathways are blocked. Death signals that result in dephosphorylation of BAD convert the BAD protein into a survival antagonist. Thus hypo-phosphorylated BAD selectively sequesters and neutralizes anti-apoptotic molecules, particularly Bcl-X L [7, 9, 10] , permitting activation of BAX and BAK, the effectors of apoptosis.
Phosphorylation of BAD at its various regulatory sites has been shown to proceed via a variety of kinases, including PKA (protein kinase A) [11, 12] , p90rsk [13] and PKB (protein kinase B) [14, 15] . The latter event is thought to play an important role in the survival effects of the PI3K (phosphoinositide 3-kinase) pathway [16] , but it may not have an essential function, or at least not in all cell types [17] [18] [19] [20] [21] . Our analysis of BAD phosphorylation revealed a site near the C-terminus, Ser 170 , as an additional site of phosphorylation involved in regulation of BAD [22] , although, to date, the precise function of this region of BAD has not been characterized. Despite widespread interest in the regulation of BAD phosphorylation, there had been few other studies investigating BAD phosphorylation at the Ser 170 site [23, 24] . Recently, Polzien et al. [26] discovered that the corresponding site in human BAD, Ser 134 , was phosphorylated in a RAF (v-raf-1 murine leukaemia viral oncogene homologue)-dependent manner and contributed to RAF's effects on tumour cell proliferation. We have also shown in our previous study that an S170A mutation enhanced the pro-apoptotic activity of BAD, whereas the S170D phospho-mimetic showed no apoptotic activity; cells expressing BAD-S170D also had an increased rate of proliferation [22] .
We have now further characterized the role for BAD phosphorylation at Ser 170 in both apoptosis regulation and cell proliferation. We found the effect on cell cycle to be specifically during S-phase. We also characterized the kinase that regulates phosphorylation of Ser 170 on BAD. The unique sequence at this site, PRPKSAG (Ser 170 is bold and underlined), does not conform to a typical phosphorylation site, but cell extracts contained robust kinase activity that we now show corresponds to CaMKII-γ (γ isoform of Ca 2 + /calmodulin-dependent kinase II). We discovered that CaMKII-γ activity is increased in response to cytokine treatment, and inhibition of CaMKII activity correlates with enhanced apoptosis, which is dependent upon its ability to phosphorylate BAD-Ser 170 . This kinase activity is higher during Sphase, supporting a role for CaMKII-γ /BAD-Ser 170 in progression through that part of the cell cycle. The ability of phospho-Ser 170 -BAD to have a profound effect on both apoptosis and cell cycle makes it a key target for future studies.
MATERIALS AND METHODS

Cell culture
FDC-P1 and MC/9 cells were maintained at 37
• C and 5% CO 2 in RPMI 1640 medium containing 10 % FBS (fetal bovine serum), 20 μM 2-mercaptoethanol and 10 % WEHI-3-conditioned medium as a source of IL-3 (interleukin 3). MEF (mouse embryonic fibroblast) cells were maintained in DMEM (Dulbecco's modified Eagle's medium) containing 10 % FBS. Retroviral-mediated expression of Bcl-X L or BAD, and the various mutant forms of BAD, was performed as described previously [22] . Briefly, retrovirus were prepared in Plat-E cells [25] plated in 6-well plates and transfected with Effectene (Qiagen) according to the manufacturer's protocol. MC/9-Bcl-X L cells were constructed using retroviral infection (the plasmid CTV 83 expressing human Bcl-X L was a gift from Dr Robert Kay BC Cancer Agency, Vancouver, Canada), and G-418 was used for selection. Stable MC/9-Bcl-X L transfectants expressing various FLAG-tagged BAD constructs in the pMX-puro vector were selected in complete medium containing 2 μg/ml puromycin, and stable clones were isolated by serial dilution in 96-well plates.
Gene silencing by siRNA (small interfering RNA)
MEF cells were grown to 70 % confluency in 60 mm dishes. Medium was changed to OptiMEM (Invitrogen) and cells were transfected with siRNA using TriFECTin (Integrated DNA Technologies) following the manufacturer's instructions. Cells were harvested 48 h later. Three different CaMKII-γ or -β siRNAs were produced by Dicer-substrate RNAi (RNA interference) kits (IDT) and were used together to knock down expression. The CaMKII-γ siRNA sequences were as follows: 5 -AGCGUAGACAGGAAGAGAAUUGGTG-3 , 5 -GGCAGA-UAACAGAGAAAGUAAUGGA-3 and 5 -GGUAAAGUCU-CGCGGUGCUGCCGGG-3 . The three CaMKII-β siRNA sequences were: 5 -AGCAAGCAACAUUUAGGUAUCACTT-3 , 5 -ACAUCUAUGUGAUAACUAGACCUCT-3 , and 5 -AGUG-CGCAAACAGGAAAUUAUCAAA-3 .
Control siRNA was provided in the kit. PCR primers used to verify knockdown of message levels of the respective kinases, and primers to detect expression of actin, were also obtained from IDT.
Immunoprecipitation and blotting
Cell lysates were prepared using ice-cold solubilization buffer (50 mmol/l Tris/HCl, pH 7.7, 10 % glycerol, 1 % Triton X-100, 100 mmol/l NaCl, 10 mmol/l NaF, 2.5 mmol/l EDTA, 1 mmol/l sodium molybdate, 0.2 mmol/l sodium vanadate and 10 μl/ml of Sigma Protease Inhibitor Cocktail) and incubated on ice for 2 min. Samples were then centrifuged at 20 000 g for 10 min, and supernatants were transferred to clean tubes. Anti-BAD antibody (BD Biosciences, 610392) was added and the samples were rotated overnight at 4
• C. BAD immunocomplexes were captured with 50 μl of 50% slurry of Protein G-agarose beads (GE Healthcare) for 1 h at 4
• C. Beads were washed four times with solubilization buffer and resuspended in 25 μl of 2×reducing sample buffer followed by boiling for 5 min. Samples were fractionated on 12.5 % polyacrylamide gels and transferred on to nitrocellulose membranes. Blots were blocked with 5 % (w/v) non-fat dried skimmed milk powder solution for 1 h and then incubated with antibodies. The antibodies used were anti-BAD (SC-943, Santa Cruz Biotechnology), anti-FLAG (F-3165, Sigma), anti-CaMKII (Santa Cruz Biotechnology, SC-9035), anti-CaMKII (phospho-specific Thr 286 ) (Upstate Biotechnology, AB3827), anti-CaMKII-γ (Upstate Biotechnology, 07-743) and anti-Chk1 (Santa Cruz Biotechnology, SC-7898).
Apoptosis assay
Apoptosis was assayed by Annexin V and/or PI (propidium iodide) staining. Samples were read using flow cytometry (BD FACSCanto) and analysed with FCS Express v.2 (DeNovo software). The cells were cultured until reaching a density of not more than 5×10 5 cells/ml, followed by washing three times with complete RPMI 1640 medium. Cells were harvested after various times of IL-3 starvation, washed with PBS twice and centrifuged at 200 g for 4 min. The pellet (5×10 5 cells) was resuspended in 500 μl of staining solution [Annexin Vfluorescein labelling reagent/PI = 1:2 (v/v)] and incubated for 15 min at room temperature (22
• C). The percentage of cells undergoing apoptosis was determined from both Annexin Vpositive cells and cells that were both Annexin V-and PI-positive. Analysis of cells at various time points verified that at early times, only Annexin V-positive cells were observed and at later times, cells became double positive.
Cell cycle synchronization and analysis
Synchronous progression through G 1 -and S-phase was obtained by arresting the cells at the G 1 /S transition by adding hydroxyurea (0.5 mM final concentration for 16 h) and subsequently washing the cells three times with PBS and transferring the cells to hydroxyurea-free medium. Synchronized cells were fixed in 70 % cold ethanol after various times, washed once in PBS containing 0.1 % glucose, and incubated for 30 min at 4
• C in PBS containing 0.1 % glucose, 10 μg/ml RNase A and 5 μg/ml PI per ml. Samples were analysed using a BD FACSCanto flow cytometer. Unsynchronized cells were sorted using a BD FACS Vantage SE Turbo cell sorter.
Kinase assay
A peptide encoding the Ser 170 site of BAD was synthesized at the Biomedical Research Centre, University of British Columbia. The synthetic peptide contained the sequence RRGGPRPKSAGVA; PRPKSAG corresponds to residues 166-172 of murine BAD or 130-136 of human BAD. CaMKII kinase assays using either cell extracts or purified CaMKII isoforms were performed using ACT III (Autocamtide III peptide; Anaspec, 29973-1), a selective substrate for CamKII isoforms. Some earlier assays were performed using the peptide substrate PLSTRLSVSS from Santa Cruz Biotechnology, which gave similar results. Chk1 kinase activity was assayed using ChkTide (Sigma) as a substrate. The kinase assay was performed by adding 5 μg of peptide substrate, 10 μl of the kinase (either from fractions collected from column chromatography, immunoprecipitated kinase or purified kinase) and 0. 
Statistics
Results are shown as means + − S.E.M. For statistical analyses, the Student's t test was used.
RESULTS
Role of phosphorylation at Ser
170 in regulating apoptotic activity of BAD Phosphorylation at the Ser 170 site on BAD was reported previously in cytokine-dependent MC/9 mast cells [22] . In the present study, we have also used FLAG-tagged BAD and the corresponding mutants (S170A and S170D) expressed via retroviral transfer in the cytokine-dependent haemopoietic progenitor cell line, FDC-P1, in which Bcl-X L was also overexpressed. Immunoblot analysis of stably infected cells demonstrated expression of the FLAG-tagged mutant forms of BAD and showed that endogenous BAD was unaffected as compared with controls ( Figure 1A ). The IL-3-dependent FDC-P1 cells and the transfected variants were measured for signs of apoptosis after 24 h of cytokine starvation. FDC-P1 cells expressing Bcl-X L were much more resistant to apoptosis following cytokine withdrawal compared with parental cells ( Figure 1B) . Expression of wt (wild-type) BAD reversed the pro-survival effect of Bcl-X L , and these cells regained cytokine-dependent survival. FDC-P1 cells expressing BAD-S170D showed much less apoptosis following cytokine starvation than the same cells expressing wt BAD. In fact, they were not significantly different from cells without the added BAD, suggesting that mutation of the Ser 170 site to a phospho-mimetic residue is able to block the pro-apoptotic effect of BAD, as we described previously in MC/9 cells.
We also tested cells expressing BAD with the S170A mutation together with three other well-described serine phosphorylation sites: Ser 112 , Ser 136 and Ser 155 . The cells expressing BAD mutant 112A/136A/155A (3SA) were very susceptible to apoptosis, and the additional mutation of Ser 170 to alanine (i.e. 4SA: 112A/136A/155A/170A) resulted in an even greater propensity to undergo apoptosis than cells expressing the 3SA mutant ( Figure 1C ). It is important to note that the level of expression of the BAD-3SA and BAD-4SA mutants was lower than what could be achieved with wt BAD, probably due to the potent apoptosispromoting effects of these proteins.
In another test of the effects of the alanine mutants, transient transfection of FDC-P1 cells that had no exogenous Bcl-X L with the various mutants were compared. As shown in Figure 2 , similar levels of expression of the BAD mutants were achieved. The 3SA or 4SA each induced apoptosis upon withdrawal of cytokine from the stable transfectants, but S170D in the 3SA mutant (3SA/D) dramatically blocked this effect. Under conditions of transient (A) FDC-P1 cells expressing Bcl-X L were retrovirally infected with FLAG-tagged BAD-S170A (S170A) or BAD-S170D (S170D). Cell extracts were separated by SDS/PAGE and immunoblotted using anti-BAD antibody. The slower migrating bands represent FLAG-tagged forms of BAD, whereas the faster migrating bands represent endogenous BAD protein. (B) Apoptosis was measured in cells in the presence of cytokine (grey bars) or following 24 h of cytokine withdrawal (black bars). The cells were parental FDC-P1, FDC-P1 expressing Bcl-X L (FDC-P1 Bcl-X L ), or the Bcl-X L -expressing cells that were also expressing wt BAD (FDC-P1 WT) or BAD-S170D (FDC-P1 D). *Cells expressing Bcl-X L or Bcl-X L and BAD-S170D were significantly different (P < 0.05) from parental cells or cells expressing wt BAD. (C) Apoptosis was measured in FDC-P1 cells expressing Bcl-X L , and subsequently retrovirally infected to express BAD-S112A/S136A/S155A (grey bars) or BAD-S112A/S136A/S155A/S170A (black bars). Cells were under normal growth conditions (Con), or starved of cytokine (Starved). *Cells expressing four alanine residues were significantly different (P < 0.05) from those expressing three alanine residues.
expression, where the 3SA or 4SA mutants caused substantial apoptosis within 72 h, the 3SA/D mutant had little effect. These results support the suggestion that BAD phosphorylation at Ser 170 suppresses the pro-apoptosis function of BAD.
Phosphorylation of BAD-Ser 170 also regulates cell proliferation and cell cycle progression
Previous work indicated that the phosphorylation of Ser 170 not only blocked the pro-apoptotic function of BAD, but also had an effect on cell proliferation [22] . Phosphorylation of the corresponding Ser 134 in human BAD also reportedly enhanced cell proliferation [26] . Supporting those results, we found that the expression of BAD-S170A in MC/9 cells expressing Bcl-X L extends doubling time (Supplementary Figure S1 available at http://www.BiochemJ.org/bj/442/bj4420139add.htm). We also observed that the BAD-S170D expressing cells tended to double in number faster than cells expressing wt BAD, at a rate similar to cells with Bcl-X L and no added BAD.
This effect was further examined by flow cytometry analysis of cell cycle status using MC/9 cells expressing Bcl-X L in the absence or presence of the BAD-Ser 170 mutants. Cells were grown in the presence of IL-3 then fixed and stained with PI. The percentage of viable cells in G 1 -, S-and G 2 -phase were calculated for control (MC/9-Bcl-X L ) and BAD-S170A or BAD-S170D cells. The percentage of cells in G 1 -, S-and G 2 -phase were nearly identical between control cells and cells expressing BAD S170D; however, cells expressing S170A showed nearly twice the number of cells in S-phase as compared with S170D and control ( Figure 3A) . As shown below, other data support a conclusion that S170A-expressing cells showed an increase in the time required to progress through S-phase.
MC/9-Bcl-X L clones expressing higher or lower levels of S170A or S170D were obtained and expression was analysed by immunoblotting with anti-FLAG antibody. S170A and S170D clones were analysed by flow cytometry following PI staining ( Figure 3B ). The S170A clone having higher expression showed a marked difference as compared with control cells and high expressing S170D, with nearly 4-fold more cells in S-phase in the S170A cells as compared with S170D. Cells with higher levels of S170D had a 2-fold decrease in the number of cells in S-phase as compared with control cells. Although the expression of the mutants caused very dramatic effects on cell proliferation, minimal apoptosis was observed in stable cell lines expressing either BAD-S170A or BAD-S170D, irrespective of expression levels, as long as cells were grown in IL-3 (results not shown). (A) MC/9-Bcl-X L and MC/9-Bcl-X L FLAG-BAD wt, S170A and S170D were fixed and stained with PI and analysed using flow cytometry. Cell cycle analysis was performed by measuring DNA content and cell size. The percentage of cells in G 1 -, S-or G 2 -phase was determined. (B) Cell cycle analysis was performed as in (A), using clonal populations of MC/9-Bcl-X L cells (Bcl X L ) expressing BAD-S170A and BAD-S170D. Cell lysates of respective clonal populations were separated by SDS/PAGE and immunoblotted using anti-FLAG antibody.
Identification of the BAD-Ser 170 kinase
Based on these intriguing effects of mutation at the BAD-Ser 170 site on both apoptosis and cell proliferation, our next aim was to identify the kinase(s) responsible for its phosphorylation. During the initial stages of this work, no antibody was available to detect this phospho-site. We used a peptide based on the sequence corresponding to the Ser 170 site in murine BAD (PRPKSAG) to assay for kinase activity. As shown below, kinase activity that phosphorylates this site could be readily assayed using extracts from MC/9 cells, as well as from other cell types, including FDC-P1 and MEFs. In the Supplementary Online Data and Supplementary Figure S2 (at http://www.BiochemJ.org/bj/442/ bj4420139add.htm), we describe experiments that lead to the identity of CaMKII as a BAD-Ser 170 kinase. In brief, after ruling out many possible candidates by use of kinase assays and selective kinase inhibitors, CaMKII became a candidate based on in silico searches. We used column chromatography to separate CaMKII enzymes and showed co-elution with BAD-Ser 170 kinase activity. An inhibitor of CaMKII isoforms, KN93, has been described that is relatively selective for this family [27] , along with a related compound, KN92, that has no inhibitory activity. We found that the peak kinase activity from the Superdex column fractionation, when used for in vitro assays against both the CaMKII substrate and the Ser 170 peptide, were both inhibited by KN93 ( Figure 4A ), whereas the inactive analogue had no inhibitory effect (results not shown). To verify that CaMKII and Chk1 protein were present in peak fractions predicted from the respective kinase assays, Superdex column fractions were separated by SDS/PAGE and immunoblotted using anti-CaMKII or anti-Chk1 antibody. The antibody to CaMKII detected bands corresponding to the β, γ or δ isoforms of the enzyme, which migrate at approximately 60-65 kDa ( Figure 4B ). These bands appeared in Superdex S200 fractions 9-12, which correspond to the peak of Ser 170 peptide and CaMKII substrate kinase activity. Chk1 enzyme was detected at approximately 50 kDa in Superdex S200 column fractions 17-19, which corresponded to the peak of activity against the ChkTide substrate. Although there was a previous suggestion that Chk1 could phosphorylate the BAD-Ser 170 site [23] , our studies ruled out Chk1 as a possible kinase, and subsequent studies focused on the activity of the isoforms of CaMKII.
An antibody raised against the phospho-Ser 134 site in human BAD, which corresponds to Ser 170 in murine BAD, was tested in cells expressing wt BAD. As can be seen in Figure 4 (C), following cytokine starvation, stimulation of MC/9 cells with IL-3 resulted in increased phosphorylation of BAD-Ser 170 , which was largely blocked by pre-incubation of the cells overnight with a low concentration of KN93, further supporting the role of CaMKII in mediating phosphorylation of BAD-Ser 170 .
Kinase activity using purified CaMKII isoforms
There are four known isoforms of CaMKII, each of which may be present in the multimeric complexes that form the holoenzyme [28] . Commercial sources of purified isoforms of CaMKII-α, -β, -γ and -δ were next tested for their ability to phosphorylate the peptide corresponding to BAD-Ser 170 or the CaMKII substrate peptide. As shown in Figure 5 (A), all of these kinases phosphorylated the CaMKII substrate, with some differences in their relative level of activity. However, when assayed using the peptide corresponding to BAD-Ser 170 , there was a striking difference in the activities, with only CaMKII-γ having robust activity. As expected, the KN93 inhibitor was able to block the activity of each of the isoforms in assays against both substrates, although in our hands it appeared to be slightly less effective against CaMKII-α.
A further confirmation of the ability of CaMKII-γ to phosphorylate the BAD protein at Ser 170 was obtained by using an in vitro kinase assay with purified CaMKII-γ to phosphorylate intact BAD ( Figure 5B ). Using an anti-FLAG immunoprecipitate of FLAG-BAD or FLAG-BAD-S170A, it was apparent that increased levels of phospho-Ser 170 could only be detected in the FLAG-BAD sample following incubation with CaMKII-γ , but not in the FLAG-BAD-S170A.
Knockdown of CaMKII-γ expression
To confirm that CaMKII-γ was the cellular kinase responsible for the BAD-Ser 170 kinase activity, we used MEF cells treated with siRNA to knockdown expression of CaMKII-γ . MEF cells were used since kinase activity against the BAD-Ser 170 peptide was easily detected in these cells, and siRNA knockdown cannot be successfully done in either MC/9 or FDC-P1 cells. MEF cell lysates had similar levels of activity against either the BAD-S170 peptide or the ACT III substrate ( Figure 6A ). When treated with siRNA specific for CaMKII-β, or CaMKII-γ , the respective message levels were decreased as expected ( Figure 6B ). The siRNA against CaMKII-β serves as a negative control for the BAD Ser 170 kinase activity, since the purified CaMKII-β was shown to have little kinase activity towards the Ser 170 peptide substrate ( Figure 5 ). siRNA specific for CaMKII-γ significantly reduced the kinase activity against Ser 170 peptide, and the activity against ACT III was partially reduced. The relatively greater effect on the kinase activity measured against BAD-Ser 170 peptide would be predicted since other isoforms can also contribute to the total CaMKII activity measured with the ACT III substrate.
Cytokine activation of CaMKII
The ability of cytokines to activate CaMKII activity has never been described. We utilized the peak kinase activity from Superdex fractionation of FDC-P1 cells, which we had shown to contain KN93-sensitive CaMKII activity that phosphorylates both the CaMKII substrate and the Ser 170 peptide. When FDC-P1 cells were deprived of cytokine for 4 h, which we have shown previously was able to almost completely suppress activity of other kinases such as PKB or ERK1/2 (extracellular-signalregulated kinase 1/2) [29] , the CaMKII activity was reduced. Consistently, we observed a 25-30 % reduction in activity in multiple experiments. Re-addition of IL-3 to the starved cells for 20 min resulted in an increase in activity back to the prestarvation levels ( Figure 7A ). The fact that cytokine starvation only caused partial suppression of CaMKII activity is consistent with our previous results showing that when cells were starved of cytokine, there was always a basal level of BAD phosphorylation specifically at the Ser 170 site, and the level of phosphorylation was increased by cytokine treatment of cells (peptide 2 in [30] ).
Similar results were obtained when CaMKII activity was assayed following immunoprecipitation from cytokine-starved cells compared with cells treated with IL-3 ( Figure 7B ). This antibody recognizes all CaMKII isoforms and thus we could not distinguish which ones were being affected, but IL-3 stimulation caused a clear activation of the kinase activity. In experiments done using an antibody specific for CaMKII-γ , a similar stimulation of kinase activity was observed following IL-3 treatment ( Figure 7C ).
All CaMKII isoforms share a conserved residue, Thr
286
(numbering from CaMKII-α), which is indicative of active enzyme, as well as Ca 2 + /CaM independent activity [31] . Consistent with potential activation of CaMKII by IL-3 stimulation, we were also able to show that IL-3 stimulation of FDC-P1 cells results in increased phosphorylation of Thr 286 detected in cell lysates ( Figure 8A ). The same experiment was repeated using an antibody specific to the CaMKII-γ isoform, to immunoprecipitate only that isoform, and a similar pattern of phosphorylation was observed in response to IL-3 stimulation ( Figure 8B ).
Apoptosis mediated by CaMKII inhibitor is dependent upon BAD-Ser 170
The role of CaMKII in mediating cytokine-dependent cell survival was tested by the use of KN93. Incubation of FDC-P1 cells with KN93 for 24 h, at 10 or 50 μM, caused apoptosis ( Figure 9A ). When cells expressing Bcl-X L were treated in the same way, there was very little cell death. Expression of BAD in cells with Bcl-X L caused them to regain cytokine-dependent survival. When incubated with KN93 (and still in the presence of cytokine), cells expressing BAD also regained sensitivity to the effects of the CaMKII inhibitor. In BAD-S170D-expressing cells, there was much less of an effect from KN93. It should be noted that the inactive analogue, KN92, did not induce apoptosis at the same concentrations under any condition. Figure 9 (B) shows a similar experiment done with the MC/9 cell line. The parental cells are very sensitive to KN93-induced apoptosis (results not shown), but expression of Bcl-X L could overcome this effect. In MC/9 cells expressing BAD or the S170A mutant form, KN93 caused cell death, but even more dramatically than in FDC-P1, the BAD S170D mutant protected the MC/9 cells from the effects of KN93. Taken together, these results demonstrate that blocking CaMKII activity, and most likely the CaMKII-γ isoform, can contribute to apoptosis in a manner that is dependent upon blocking phosphorylation of BAD at Ser 170 .
Cell cycle progression is also regulated by CaMKII-γ via BAD-Ser 170
Having shown that Ser 170 phosphorylation of BAD had an important role in both apoptosis and cell proliferation, and this phosphorylation was at least partially mediated by CaMKII-γ , we further investigated the cell-cycle-related events. As shown above, MC/9 cells expressing BAD-S170A compared with BAD-S170D showed major differences in the number of cells in S phase (Figure 3 ). To monitor S-phase progression, cells were synchronized in G 1 -phase by incubation in hydroxyurea, and released at various time points. The decrease in cell numbers in G 1 -phase was similar in each cell type and most cells had left G 1 and entered S-phase by 6 h ( Figure 10A ). Cells entered and exited from S-phase and began to enter G 2 after 4 h. In all cases, except for BAD-S170A expressing cells, the time at which most cells had completed S-phase was 8 h. The MC/9-BAD-S170A cells took much longer time to transit through S-phase, and were delayed in their transition to G 2 . Although these analyses cannot distinguish among possible causes, it is clear that expression of BAD-S170A causes a prolonged S-phase.
In similar cell cycle analyses using hydroxyurea block and release, we asked whether we could detect differences in the activity of CaMKII that would explain a possible connection between phosphorylation of BAD-Ser 170 and cell proliferation. Cells were synchronized by hydroxyurea treatment and released. As shown in Figure 10(B) , the KN93-inhibitable activity against either CaMKII substrate or the BAD-Ser 170 peptide substrate each showed a significant increase at the time when a majority of cells were in S-phase. Cell sorting by FACS was also used to separate cells in G 1 /S/G 2 -phase without any drug treatment. Similar results were obtained, showing that cells in S-phase had a higher relative level of kinase activity against the Ser 170 peptide ( Figure 10C ). While these experiments alone have not shown that this activity is solely due to CaMKII-γ , the studies above suggest that the primary activity against the BAD-Ser 170 peptide that is elevated during S-phase can be attributable to CaMKII-γ .
DISCUSSION
The mechanisms by which the Bcl-2 family controls mitochondrial-mediated cell death have been investigated in numerous studies in the past decade. The BH3-only subfamily of proteins can act as 'sensitizers' since they influence the apoptotic response, but are unable to directly disrupt the mitochondrial membrane as can be done by BAX and BAK. BAD is one of the most intriguing BH3-only proteins, since it has a unique role as a sensor of multiple upstream kinases that target its phosphorylation. BAD phosphorylation at Ser 112 and Ser 136 allows association with cytosolic 14-3-3 proteins, whereas phosphorylation at Ser 155 , in the BH3 domain, disrupts association with Bcl-X L and Bcl-2. Phosphorylation of BAD at Ser 170 also regulates BAD's pro-apoptotic activity [22] . We have now further characterized the role of the Ser 170 site, including in the context of phosphorylation at the other sites, using multiple approaches to show the important role of phosphorylation at Ser 170 . We also further characterized an effect of BAD phosphorylation at Ser 170 on cell cycle regulation, which had been suggested by our earlier studies [22] . No previous studies had attempted to characterize phosphorylation at this site, but during the preparation of the present paper, a study from Polzien et al. [26] showed phosphorylation at the corresponding site in human BAD regulated RAF-mediated proliferation of HEK (human embryonic kidney)-293 cells or HeLa cells.
When the Ser 170 phosphorylation site was first described, we had shown that its phosphorylation was not dependent upon either PI3K/PKB or MEK [MAPK (mitogen-activated protein kinase)/ERK kinase]/ERK-dependent pathways [22, 30] . Another study reported that a peptide with this phosphorylation site could be phosphorylated by Chk1 [23] . We also utilized a Ser 170 -containing peptide substrate for characterization of the BADSer 170 kinase. We could readily detect kinase activity in cell extracts that phosphorylated the peptide, and numerous kinase inhibitors were mostly ineffective. We have shown in the present study that the activity that is responsible for phosphorylation of the BAD-Ser 170 peptide corresponds to CaMKII-γ , but not Chk1. The use of a selective inhibitor of CaMKII, KN93, reinforces the identity of the Ser 170 kinase as CaMKII. Furthermore, kinase activity of immunoprecipitated CaMKII and CaMKII-γ also showed activity against the Ser 170 site. The activity was decreased following cytokine starvation of cells, and activated by treatment of starved cells with cytokine. We only saw a partial reduction in CaMKII activity during 4 h of cytokine starvation, consistent with the observation we made previously showing that the Ser 170 site in BAD is always phosphorylated to some extent in cytokine-starved cells, and its phosphorylation increases, along with other sites in BAD, upon cytokine stimulation.
Assays of the four CaMKII isoforms showed a striking difference in their ability to phosphorylate this site. Each of the purified enzymes could phosphorylate the CaMKII substrate, and the activity was inhibited by KN93, but only CaMKII-γ phosphorylated the BAD-Ser 170 peptide. Knockdown of CaMKII-γ , but not CaMKII-β, resulted in a suppression of the BAD-Ser 170 kinase activity, which reinforced the identity of the kinase as CaMKII-γ . Among the four isoforms, CaMKII-γ has been shown to be the major one expressed in myeloid cells and its potential role as a regulation of leukaemic potential has been discussed [32] . Comparison of the four isoforms of CaMKII shows that they are highly homologous, particularly in the kinase domain. The Ser 170 site in BAD is a non-conventional site of phosphorylation that is unlike other known kinase substrates. Therefore it will be interesting to investigate the features of the CaMKII-γ enzyme that results in its unique ability to phosphorylate BAD at Ser 170 . An important potential reagent to facilitate future studies would be an inhibitor with selective effects only against the CaMKII-γ isoform. Further study of the role of CaMKII-γ in promoting cell survival will also have to consider the multimeric structure of CaMKII enzymes, which can include multiple isoforms [28] . It will be important to determine whether the γ isoform may participate in complexes with other CaMKII isoforms, and how these are involved in regulating the function of BAD.
We have strong evidence that phosphorylation of BAD-Ser 170 by CaMKII has a pro-survival effect in experiments done in either FDC-P1 or MC/9 cells using the KN93 inhibitor. In parental cells, KN93 induces apoptosis, whereas overexpression of Bcl-X L largely overcomes the pro-apoptotic effect. Expression of BAD in Bcl-X L -expressing cells reinstates the cytokine-dependent survival, and under these conditions KN93 can cause apoptosis.
However, when cells expressing Bcl-X L and BAD-S170D were treated with KN93, there was little to no apoptosis, further supporting the suggestion that CaMKII (probably CaMKII-γ )-mediated phosphorylation of BAD at Ser 170 blocks the proapoptotic activity of BAD.
Several reports regarding the role of CaMKII in apoptosis have yielded inconsistent conclusions. In studies using various cell systems, CaMKII activity has either been associated with inhibition of apoptosis [33] [34] [35] [36] , or in promoting apoptosis [37] [38] [39] . The reasons for the variable reports could be related to the differential expression of the four isoforms (and several reported splice variants), and thus careful analysis of expression will be necessary to delineate specific functions. In a previous study, the potential survival effect of CaMKII on neuronal cells was investigated, and CaMKII overexpression was shown to overcome apoptosis induced by expression of BAD [40] . In that study, analysis of BAD phosphorylation was not possible, but it is intriguing to speculate that BAD phosphorylation at Ser 170 may be involved.
Future studies will also need to address which protein interactions may be mediated by the domain of BAD encoding the Ser 170 site, and how phosphorylation of that site affects those interactions. For example, we know that BAD-S170D, although having a greatly diminished pro-apoptotic activity, can still bind to Bcl-X L [22] . However, we have not determined whether these interactions occur in the cytosol or at the mitochondrial membrane. Another interesting question is whether BAD phosphorylated at Ser 170 affects the binding to specific 14-3-3 isoforms. Any Ser 170 -dependent interactions will provide clues as to the mechanism of action of the phosphorylated Ser 170 site. In addition to our earlier study suggesting a role for BAD in cell proliferation [22] , others have also suggested that BAD can have effects on cell cycle progression unrelated to its regulation of apoptosis [41, 42] . In a study examining the effects of Bcl-2 and Bcl-X L on slowing cell cycle progression, co-transfection of BAD was able to reverse the effect [43] , which is consistent with our observations that BAD phosphorylated at Ser 170 can have a positive effect on cell cycle progression. More recently, the role of Ser 134 phosphorylation in human BAD was also tied to cell proliferation via RAF [26] , supporting the findings of the present study. The latter study suggests that RAF and PAK1 [p21 protein (Cdc42/Rac)-activated kinase 1] may serve as kinases that directly phosphorylate BAD, but this is not proven based on the experimental approach which involved co-transfection of the kinases and BAD in HEK-293 or HeLa cells. These intriguing results showing that RAF, PAK1 or CaMKII-γ can be upstream of the same phosphorylation site makes the characterization of a potential RAF or PAK1 to CaMKII-γ pathway intriguing. Or, can each of these kinases directly target the Ser 170 site? It is clear from knockout mouse studies that loss of BAD does not have a major effect on development [44] , and thus it is unlikely to play an essential role in cell cycle regulation. However, it is possible that a cell cycle function is only detectable under specific conditions, such as in cellular stress or under certain metabolic situations. Alternatively, in the absence of BAD, other regulatory proteins may carry out its functions in cell cycle regulation. With respect to metabolic regulation, BAD function at the mitochondria has also been linked to glucose metabolism [45] . The many intriguing functions of BAD that may function separately from its pro-apoptotic activity via the BH3 domain binding, cannot yet be explained mechanistically, but will surely lead to many further studies in this field.
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SUPPLEMENTARY ONLINE
MATERIALS AND METHODS
Growth curves
MC/9 cells expressing Bcl-X L alone, or with wt BAD, BAD-S170A or BAD-S170D, were plated at 25 000 cells per well in six-well tissue culture dishes in medium supplemented with 10 % FBS and WEHI-3. On days 1, 2, 3 and 4, three wells from each cell line were harvested and the cell number was determined with a Coulter counter (Beckman-Coulter). The average number of cells per well and the S.E.M. were generated for each cell line at each time point.
Column chromatography
Cells were pelleted at 200 g for 4 min and washed, followed by lysis with ice-cold solubilization buffer. Lysates were centrifuged at 20 000 g for 10 min at 4 • C to remove the nuclei and insoluble material. The supernatant was then loaded on to a Mono Q HR 5/5 column (Pharmacia). Mono Q buffer A contained 50 mM Tris/HCl, pH 8.8, 2.5 mM EDTA, 1 mM sodium orthovanadate and 0.01 % Triton X-100. Mono Q buffer B was the same as buffer A except that it also contained 1 M NaCl, and a linear gradient of 0 to 1 M NaCl was used to elute bound proteins. Samples of 0.5 ml were collected at a flow rate of 0.25 ml/min. For Superdex S200 column fractionation, the cell extracts were loaded and the column was washed with buffer containing 50 mM Tris/HCl, pH 7.7, and 0.05 % Triton X-100. Fractions of 0.5 ml were collected with a flow rate of 0.25 ml/min.
RESULTS
Initial characterization of the BAD-Ser 170 kinase
We first tested a battery of known kinase inhibitors to obtain clues regarding the identity of the kinase. Many well-characterized kinase inhibitors, including LY-294002, wortmannin, U0126, rapamycin, SB203580 and Ro-31-8220, had little or no effect at concentrations where they are known to selectively block various protein kinases (results not shown). We also used standard in vitro kinase assays, following the immunoprecipitation of a series of kinases: PKB, ERK1/2, CDK (cyclin-dependent kinase)-2, CDK-4, CDK-6 and GSK3 (glycogen synthase kinase 3), but none showed significant activity against the peptide compared with their corresponding activity against standard substrates (results not shown).
A search for potential protein kinases that may phosphorylate the Ser 170 site of BAD was carried out using ScanProsite (http://expasy.org/tools/scanprosite/) against the SwissProt database. The short sequence PRPKS was found to be very rare, with only 37 hits found (three of which were BAD proteins in humans, mice and rats). A motif scan under high stringency was performed on all 37 proteins to analyse potential serine/threonine phosphorylation sites. Ser 846 within the protein mSulf-1 was the only site yielding a predicted kinase. In this case, CaMKII was predicted to be a possible kinase that phosphorylated this site, although there are no publications to support such a connection. It had been reported that the checkpoint kinase Chk1 was able to phosphorylate the Ser 170 site in BAD [1] . As described below, these two kinases were further investigated to determine their potential role in phosphorylating the Ser 170 site of BAD. The separation of BAD-Ser 170 kinase activity by column chromatography was performed. MC/9 cell lysates were separated by MonoQ and Superdex S200 fractionation. MonoQ fractionation resulted in a single peak of kinase activity that co-migrated when fractions were assayed using the peptide corresponding to BAD-Ser 170 or the peptide PLSTRLSVSS as a CaMKII substrate ( Figure S2A ). The peak eluted between 0.4 and 0.5 M NaCl. In subsequent studies, the same profile was obtained when using the Autocamtide III substrate (results not shown). When the same column fractions were assayed using a peptide that is commonly used to detect Chk1 activity (ChkTide), there were two major peaks of activity that eluted at earlier points in the salt gradient ( Figure S2B ). This result suggested that Chk1 was unlikely to be the kinase responsible for Ser 170 phosphorylation. Superdex S200 fractionation also showed a single major peak of kinase activity that was capable of phosphorylating the BADSer 170 peptide. This peak was centred at an approximate molecular mass of 400-500 kDa and overlapped with a peak of activity measured against the CaMKII substrate ( Figure S2C ). As shown in Figure S2(D) , the same fractions assayed against a peptide used to detect Chk1 activity showed a partially overlapping profile, but the major peaks of activity were clearly distinct, and the Chk1 activity migrated with a much smaller apparent molecular mass. It is important to note that the migration of the CaMKII activity with an apparent size of greater than 440 kDa is expected for the multimeric forms of this kinase [2] .
Column separation of lysates from FDC-P1 resulted in kinase profiles that were virtually identical to those obtained with lysates from MC/9 cells (results not shown). As discussed in the main text, a similar profile was also obtained from non-haemopoietic cells. Unfortunately, despite numerous attempts, we found that most of the kinase activity was lost following any combination of these two column purification steps and thus further purification by conventional chromatography was not pursued. , BAD-S170A (S170A) or BAD-S170D (S170D) were stained with PI and Annexin V. Using flow cytometry, apoptosis was calculated as the percentage of cells showing Annexin V-positive staining. (C) MC/9-Bcl-X L cells expressing wt BAD, BAD-S170A or BAD S170D were seeded at a concentration of 25 000 cells/ml and cell numbers were counted every 24 h for 5 days. The rate is defined as the multiple of times a cell doubles every 24 h. The doubling time is defined as the amount of time (in hours) required for cells to double in number.
